Congress blocks hospitals from funding transgender care with drug savings

What it does

This bill prohibits hospitals and other healthcare providers participating in the 340B drug discount program from using their drug-cost savings to fund gender-affirming surgeries and hormone therapies for transgender patients. The 340B program allows covered entities to purchase outpatient drugs at steep discounts; this bill blocks them from redirecting those savings to pay for these specific medical services.

Why we flagged it

The bill's operative mechanism is a targeted prohibition on a specific use of existing drug-discount savings. It does not expand or contract the 340B program itself, but narrows how participating entities may deploy those savings—functioning as a restriction on care access rather than a programmatic reform.

What the text implies

• The bill does not define 'gender alteration' or establish clinical criteria, creating ambiguity about which treatments are prohibited—potentially capturing hormone therapies prescribed for non-transition purposes (e.g., hormone replacement therapy for menopausal symptoms in transgender patients).
• 340B savings are typically reinvested in safety-net care; blocking one use may redirect those funds to other services, but the bill does not specify alternative uses, leaving the fate of those savings unclear.
• The prohibition applies only to 340B entities (hospitals, federally qualified health centers, etc.), not to private insurers or other payers—creating a two-tier system where access depends on insurance type and provider participation status.
• No enforcement mechanism, penalty, or audit procedure is specified in the text, raising questions about how compliance will be monitored or violations addressed.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Transgender patients lose access to a funding mechanism for gender-affirming medical care. The bill narrows the pool of affordable care options by prohibiting one class of healthcare providers (340B participants) from using their drug savings to subsidize these services, shifting cost burden onto patients or eliminating access entirely at those facilities.

Named in the bill

340B covered entities, Public Health Service Act, transgender patients, hospitals, federally qualified health centers

Where it stands

10 cosponsors: 10 Republicans.

• Mar 18, 2025 — Introduced · Congress.gov: “Introduced in House”
• Mar 18, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $725,164 in lobbying spend. A filing names 120 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Dusty Johnson, the sponsor, reported $325,500 in PAC receipts in the 2026 cycle.

• Human Rights Campaign — $439,908 on 2 filings
• 340b Health — $285,256 on 1 filing

Lobbying Disclosure Act filings through Jul 17, 2026. A filing shows who paid to lobby on a bill it names, not what changed.